Novo Nordisk A/S (NYSE:NVO) Stock Sale Disclosed by Rep. Kevin Hern

Representative Kevin Hern (Republican-Oklahoma) recently sold shares of Novo Nordisk A/S (NYSE:NVO). In a filing disclosed on September 25th, the Representative disclosed that they had sold between $1,001 and $15,000 in Novo Nordisk A/S stock on September 10th. The trade occurred in the Representative’s “KEVIN HERN TRADITIONAL IRA” account.

Representative Kevin Hern also recently made the following trade(s):

• Sold $15,001 – $50,000 in shares of CenterPoint Energy (NYSE:CNP) on 9/15/2026.
• Sold $1,001 – $15,000 in shares of TJX Companies (NYSE:TJX) on 9/15/2026.
• Sold $15,001 – $50,000 in shares of STERIS (NYSE:STE) on 9/15/2026.
• Sold $1,001 – $15,000 in shares of Seagate Technology (NASDAQ:STX) on 9/15/2026.
• Sold $15,001 – $50,000 in shares of NextEra Energy (NYSE:NEE) on 9/14/2026.
• Sold $1,001 – $15,000 in shares of Marsh & McLennan Companies (NYSE:MRSH) on 9/14/2026.
• Sold $15,001 – $50,000 in shares of IQVIA (NYSE:IQV) on 9/14/2026.
• Sold $15,001 – $50,000 in shares of Home Depot (NYSE:HD) on 9/14/2026.
• Sold $1,001 – $15,000 in shares of Home Depot (NYSE:HD) on 9/14/2026.
• Sold $15,001 – $50,000 in shares of Emerson Electric (NYSE:EMR) on 9/14/2026.

Novo Nordisk A/S Trading Down 0.3%

Shares of NYSE NVO opened at $38.69 on Tuesday. Novo Nordisk A/S has a twelve month low of $35.12 and a twelve month high of $64.16. The firm has a market cap of $172.77 billion, a PE ratio of 9.46, a price-to-earnings-growth ratio of 1.27 and a beta of 0.74. The business has a fifty day simple moving average of $45.51 and a two-hundred day simple moving average of $43.87. The company has a quick ratio of 0.66, a current ratio of 0.87 and a debt-to-equity ratio of 0.55.

Novo Nordisk A/S (NYSE:NVO) last announced its quarterly earnings results on Tuesday, June 30th. The company reported $0.94 EPS for the quarter. The firm had revenue of $11.98 billion for the quarter. Novo Nordisk A/S had a return on equity of 58.61% and a net margin of 35.36%. Analysts expect that Novo Nordisk A/S will post 3.54 earnings per share for the current fiscal year.

Novo Nordisk A/S Cuts Dividend

The company also recently disclosed a dividend, which was paid on Tuesday, August 25th. Shareholders of record on Monday, August 17th were issued a dividend of $0.5786 per share. This represents a yield of 258.0%. The ex-dividend date was Monday, August 17th. This is a decrease from Novo Nordisk A/S’s previous dividend of $1.2751. Novo Nordisk A/S’s dividend payout ratio (DPR) is 20.05%.

More Novo Nordisk A/S News

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: CagriSema produced a meaningful clinical win. In the Phase 3 REIMAGINE 5 trial, adults with type 2 diabetes receiving the 1 mg/1 mg dose lost an estimated 12.4% of body weight after 60 weeks, giving Novo a result that compares favorably with Eli Lilly’s tirzepatide and potentially strengthens the company’s comeback prospects. Novo Nordisk Just Beat Lilly in a Trial. Is the Comeback Finally Taking Shape?
• Positive Sentiment: Novo is expanding its delivery-technology capabilities. The company agreed to license Nanexa’s PharmaShell technology in a deal worth up to €1.165 billion, potentially supporting longer-acting drug formulations and strengthening its future obesity and diabetes pipeline. Novo Nordisk Licenses Nanexa’s PharmaShell In Deal Worth Up To EUR 1.165 Bln
• Positive Sentiment: Share repurchases provide support. Novo continues a buyback program of up to DKK 15 billion over 12 months, which could help support per-share value and signal management’s confidence in the depressed valuation. Novo Nordisk A/S – share repurchase programme
• Neutral Sentiment: Citi maintained a DKK 310 price target while the shares traded near DKK 253, indicating substantial potential upside but no change in the bank’s current view. Novo Nordisk stock trades at DKK 253.00 as Citi keeps target at DKK 310.00
• Negative Sentiment: Competition is broadening. Roche reported mid-stage data showing its experimental enicepatide improved blood sugar control and delivered 15.5% average weight loss, adding another potential rival to Novo’s obesity portfolio. Can Roche’s Latest Obesity Drug Results Help it Challenge Eli Lilly and Novo Nordisk?
• Negative Sentiment: Investors remain concerned that Eli Lilly is tightening its grip on the U.S. GLP-1 market and that Novo has yet to demonstrate a convincing “second act” beyond its flagship weight-loss franchise. CFRA’s bearish stance reinforces those concerns.

Institutional Investors Weigh In On Novo Nordisk A/S

Several institutional investors have recently added to or reduced their stakes in NVO. CoreCap Advisors LLC increased its position in Novo Nordisk A/S by 4.7% in the second quarter. CoreCap Advisors LLC now owns 5,341 shares of the company’s stock worth $256,000 after purchasing an additional 242 shares during the last quarter. Carson Advisory Inc. lifted its position in Novo Nordisk A/S by 2.2% during the first quarter. Carson Advisory Inc. now owns 12,316 shares of the company’s stock valued at $453,000 after purchasing an additional 268 shares during the last quarter. Bradley Foster & Sargent Inc. CT lifted its position in Novo Nordisk A/S by 0.6% during the first quarter. Bradley Foster & Sargent Inc. CT now owns 46,960 shares of the company’s stock valued at $1,726,000 after purchasing an additional 272 shares during the last quarter. Arlington Partners LLC grew its stake in shares of Novo Nordisk A/S by 4.4% in the 2nd quarter. Arlington Partners LLC now owns 6,777 shares of the company’s stock worth $325,000 after buying an additional 283 shares in the last quarter. Finally, Parkside Financial Bank & Trust increased its holdings in shares of Novo Nordisk A/S by 13.1% in the 2nd quarter. Parkside Financial Bank & Trust now owns 2,436 shares of the company’s stock worth $117,000 after buying an additional 283 shares during the last quarter. Institutional investors and hedge funds own 11.54% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on the stock. HSBC restated a “hold” rating on shares of Novo Nordisk A/S in a report on Thursday, September 10th. Nordea Equity Research raised Novo Nordisk A/S from a “hold” rating to a “buy” rating in a research report on Friday, June 19th. Wall Street Zen lowered Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research report on Saturday, June 20th. Weiss Ratings upgraded Novo Nordisk A/S from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Wednesday, August 5th. Finally, BMO Capital Markets reaffirmed a “market perform” rating and set a $47.00 price objective on shares of Novo Nordisk A/S in a research report on Thursday, August 6th. Three investment analysts have rated the stock with a Buy rating, fourteen have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Novo Nordisk A/S presently has a consensus rating of “Hold” and a consensus target price of $64.94.

About Representative Hern

Kevin Hern (Republican Party) is a member of the U.S. House, representing Oklahoma’s 1st Congressional District. He assumed office on November 13, 2018. His current term ends on January 3, 2027.

Hern (Republican Party) is running for re-election to the U.S. House to represent Oklahoma’s 1st Congressional District. He declared candidacy for the 2026 election.

Kevin Hern went into business as a McDonald’s franchisee in 1999. He acquired 10 McDonald’s franchises by 2012. He served on the McDonald’s National Leadership Team for 13 years, including the tax policy team, the insurance corporation, and as chairman of the economics team. From 2011 to 2015, he was chairman of the finance committee of the Oklahoma Turnpike Authority.

About Novo Nordisk A/S

Novo Nordisk A/S is a Denmark-based global pharmaceutical company focused on treatments for diabetes, obesity and other serious chronic diseases. Its portfolio includes injectable and oral medicines for diabetes, including insulin products and the GLP-1 therapies Ozempic and Rybelsus, as well as the obesity treatment Wegovy.

The company also develops and markets products for rare blood disorders, including hemophilia, along with growth hormone therapies and hormone replacement treatments.